This application supports the participation of the University of Chicago in Cancer and Leukemia Group B (CALGB) trials, including scientific and regulatory activities. The CALGB develops and performs clinical trials, primarily large scale clinical trials, to advance the treatment of cancer patients. The University of Chicago is a leading member of CALGB, supplying scientific and administrative leadership including the Group Chair (Dr Schilsky), Committee Chairs (Drs Ratain, Vokes, and Larson), and Study Chairs. Preliminary studies performed at the University of Chicago are taken to CALGB for large scale testing. Laboratories at the University of Chicago perform correlative studies that support CALGB trials. University of Chicago senior faculty mentor junior faculty and fellows in cooperative group participation, with large meeting attendance and eight CALGB Foundation grants awarded to University of Chicago fellows and junior faculty during the past granting period. In addition, The University of Chicago and its eight affiliate institutions are consistently among the top five accruers to CALGB studies with broad participation across all tumor types and substantial minority accrual.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA041287-27
Application #
8249784
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1986-09-30
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
27
Fiscal Year
2012
Total Cost
$258,606
Indirect Cost
$92,833
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
DeBoer, Rebecca; Koval, Gregory; Mulkey, Flora et al. (2016) Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 57:2298-306
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wang, Xiaofei; Gu, Lin; Zhang, Ying et al. (2015) Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer 90:281-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Dressler, Lynn G; Deal, Allison M; Owzar, Kouros et al. (2015) Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst 107:
Wetzler, Meir; Watson, Dorothy; Stock, Wendy et al. (2014) Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 99:111-5

Showing the most recent 10 out of 204 publications